Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Helicobacter pylori infection and eradication therapy on gastric microbiota
ChiCTR1900024893Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esomeprazole, bismuth subcitrate, amoxicillin and clarithromycin in Helicobacter pylori infection (8 arms), sponsored by Peking University Third Hospital. Primary endpoints: Gastric microbiota structure change and Fecal microbiota structure change. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
esomeprazolebismuth subcitrateamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR1900024893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024893.